# Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care

> **NCT06660719** · PHASE3 · RECRUITING · sponsor: **Shin Poong Pharmaceutical Co. Ltd.** · enrollment: 852 (estimated)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** SP-8203
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06660719
- **Lead sponsor:** Shin Poong Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-14
- **Primary completion:** 2027-03-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 852 (ESTIMATED)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06660719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06660719, "Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06660719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*